The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid

Irene L. Wapnir, Michael Goris, Anthony Yudd, O. Dohán, Donna Adelman, Kent Nowels, Nancy Carrasco

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Purpose: The Na+/I- symporter (NIS) is a key plasma membrane protein that mediates active iodide (I-) transport in the thyroid, lactating breast, and other tissues. Functional NIS expression in thyroid cancer accounts for the longstanding success of radioactive iodide (131I) ablation of metastases after thyroidectomy. Breast cancer is the only other cancer demonstrating endogenous functional NIS expression. Until now, NIS activity in breast cancer metastases (BCM) was unproven. Experimental Design: Twenty-seven women were scanned with 99mTcO4 - or 123I- to assess NIS activity in their metastases. An 131I dosimetry study was offered to patients with I--accumulating tumors. Selective down-regulation of thyroid NIS was tested in 13 patients with T3 and in one case with T3 + methimazole (MMI; bloeks I- organification). NIS expression was evaluated in index and/or metastatic tumor samples by immunohistochemistry. Results: I- uptake was noted in 25% of NIS-expressing tumors (two of eight). The remaining cases did not show NIS expression or activity. Thyroid I- uptakes were decreased to ≤2.8% at 24 h in T 3-treated patients and 1/100 normal with T3/MMI. Uptake (2.9%) was calculated in a peribronchial metastasis on 131I dosimetry scans at 4 h with disappearance of the signal by 24 h. We estimated a therapeutic dose of 3000 cGy could be achieved in this metastasis with 100 mCi Of 131 if the tumor exhibited the same dynamics as the T 3/MMI-suppressed thyroid. Conclusions: This is the first article of in vivo, scintigraphically detected, NIS-mediated I- accumulation in human BCM. T3/MMI down-regulation of thyroid NIS makes 131I-radioablation of BCM possible with negligible thyroid uptake and radiation damage.

Original languageEnglish
Pages (from-to)4294-4302
Number of pages9
JournalClinical Cancer Research
Volume10
Issue number13
DOIs
Publication statusPublished - Jul 1 2004

Fingerprint

Symporters
Iodides
Thyroid Gland
Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Down-Regulation
Methimazole
Sodium Pertechnetate Tc 99m
Thyroidectomy
Thyroid Neoplasms
Blood Proteins
Membrane Proteins
Breast
Research Design
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. / Wapnir, Irene L.; Goris, Michael; Yudd, Anthony; Dohán, O.; Adelman, Donna; Nowels, Kent; Carrasco, Nancy.

In: Clinical Cancer Research, Vol. 10, No. 13, 01.07.2004, p. 4294-4302.

Research output: Contribution to journalArticle

Wapnir, Irene L. ; Goris, Michael ; Yudd, Anthony ; Dohán, O. ; Adelman, Donna ; Nowels, Kent ; Carrasco, Nancy. / The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 13. pp. 4294-4302.
@article{12e7312586b74aa4981ac32dc476530c,
title = "The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid",
abstract = "Purpose: The Na+/I- symporter (NIS) is a key plasma membrane protein that mediates active iodide (I-) transport in the thyroid, lactating breast, and other tissues. Functional NIS expression in thyroid cancer accounts for the longstanding success of radioactive iodide (131I) ablation of metastases after thyroidectomy. Breast cancer is the only other cancer demonstrating endogenous functional NIS expression. Until now, NIS activity in breast cancer metastases (BCM) was unproven. Experimental Design: Twenty-seven women were scanned with 99mTcO4 - or 123I- to assess NIS activity in their metastases. An 131I dosimetry study was offered to patients with I--accumulating tumors. Selective down-regulation of thyroid NIS was tested in 13 patients with T3 and in one case with T3 + methimazole (MMI; bloeks I- organification). NIS expression was evaluated in index and/or metastatic tumor samples by immunohistochemistry. Results: I- uptake was noted in 25{\%} of NIS-expressing tumors (two of eight). The remaining cases did not show NIS expression or activity. Thyroid I- uptakes were decreased to ≤2.8{\%} at 24 h in T 3-treated patients and 1/100 normal with T3/MMI. Uptake (2.9{\%}) was calculated in a peribronchial metastasis on 131I dosimetry scans at 4 h with disappearance of the signal by 24 h. We estimated a therapeutic dose of 3000 cGy could be achieved in this metastasis with 100 mCi Of 131 if the tumor exhibited the same dynamics as the T 3/MMI-suppressed thyroid. Conclusions: This is the first article of in vivo, scintigraphically detected, NIS-mediated I- accumulation in human BCM. T3/MMI down-regulation of thyroid NIS makes 131I-radioablation of BCM possible with negligible thyroid uptake and radiation damage.",
author = "Wapnir, {Irene L.} and Michael Goris and Anthony Yudd and O. Doh{\'a}n and Donna Adelman and Kent Nowels and Nancy Carrasco",
year = "2004",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0074",
language = "English",
volume = "10",
pages = "4294--4302",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid

AU - Wapnir, Irene L.

AU - Goris, Michael

AU - Yudd, Anthony

AU - Dohán, O.

AU - Adelman, Donna

AU - Nowels, Kent

AU - Carrasco, Nancy

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Purpose: The Na+/I- symporter (NIS) is a key plasma membrane protein that mediates active iodide (I-) transport in the thyroid, lactating breast, and other tissues. Functional NIS expression in thyroid cancer accounts for the longstanding success of radioactive iodide (131I) ablation of metastases after thyroidectomy. Breast cancer is the only other cancer demonstrating endogenous functional NIS expression. Until now, NIS activity in breast cancer metastases (BCM) was unproven. Experimental Design: Twenty-seven women were scanned with 99mTcO4 - or 123I- to assess NIS activity in their metastases. An 131I dosimetry study was offered to patients with I--accumulating tumors. Selective down-regulation of thyroid NIS was tested in 13 patients with T3 and in one case with T3 + methimazole (MMI; bloeks I- organification). NIS expression was evaluated in index and/or metastatic tumor samples by immunohistochemistry. Results: I- uptake was noted in 25% of NIS-expressing tumors (two of eight). The remaining cases did not show NIS expression or activity. Thyroid I- uptakes were decreased to ≤2.8% at 24 h in T 3-treated patients and 1/100 normal with T3/MMI. Uptake (2.9%) was calculated in a peribronchial metastasis on 131I dosimetry scans at 4 h with disappearance of the signal by 24 h. We estimated a therapeutic dose of 3000 cGy could be achieved in this metastasis with 100 mCi Of 131 if the tumor exhibited the same dynamics as the T 3/MMI-suppressed thyroid. Conclusions: This is the first article of in vivo, scintigraphically detected, NIS-mediated I- accumulation in human BCM. T3/MMI down-regulation of thyroid NIS makes 131I-radioablation of BCM possible with negligible thyroid uptake and radiation damage.

AB - Purpose: The Na+/I- symporter (NIS) is a key plasma membrane protein that mediates active iodide (I-) transport in the thyroid, lactating breast, and other tissues. Functional NIS expression in thyroid cancer accounts for the longstanding success of radioactive iodide (131I) ablation of metastases after thyroidectomy. Breast cancer is the only other cancer demonstrating endogenous functional NIS expression. Until now, NIS activity in breast cancer metastases (BCM) was unproven. Experimental Design: Twenty-seven women were scanned with 99mTcO4 - or 123I- to assess NIS activity in their metastases. An 131I dosimetry study was offered to patients with I--accumulating tumors. Selective down-regulation of thyroid NIS was tested in 13 patients with T3 and in one case with T3 + methimazole (MMI; bloeks I- organification). NIS expression was evaluated in index and/or metastatic tumor samples by immunohistochemistry. Results: I- uptake was noted in 25% of NIS-expressing tumors (two of eight). The remaining cases did not show NIS expression or activity. Thyroid I- uptakes were decreased to ≤2.8% at 24 h in T 3-treated patients and 1/100 normal with T3/MMI. Uptake (2.9%) was calculated in a peribronchial metastasis on 131I dosimetry scans at 4 h with disappearance of the signal by 24 h. We estimated a therapeutic dose of 3000 cGy could be achieved in this metastasis with 100 mCi Of 131 if the tumor exhibited the same dynamics as the T 3/MMI-suppressed thyroid. Conclusions: This is the first article of in vivo, scintigraphically detected, NIS-mediated I- accumulation in human BCM. T3/MMI down-regulation of thyroid NIS makes 131I-radioablation of BCM possible with negligible thyroid uptake and radiation damage.

UR - http://www.scopus.com/inward/record.url?scp=3042811612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042811612&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0074

DO - 10.1158/1078-0432.CCR-04-0074

M3 - Article

C2 - 15240514

AN - SCOPUS:3042811612

VL - 10

SP - 4294

EP - 4302

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -